伴侶動物疼痛管理市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年，全球伴侶動物疼痛管理市場規模達19億美元，預計2034年將以6.2%的複合年成長率成長至34億美元。寵物慢性病發病率的不斷上升推動了這一穩定成長，也導致了對有效疼痛緩解解決方案的需求增加。此外，獸醫治療技術的進步和專用疼痛管理機構數量的不斷增加也為市場擴張做出了重要貢獻。隨著獸醫照護水準的提高，伴侶動物的壽命也隨之延長，骨關節炎、術後不適和癌症相關疼痛等疾病也變得越來越普遍，對便利高效的疼痛管理工具的需求也隨之增加。該行業涵蓋了各種藥品，例如非類固醇抗發炎藥、鴉片類藥物和麻醉藥，以及旨在緩解犬、貓、馬等動物急性和慢性疼痛的醫療器材。

2021年至2023年間，市場呈現持續的年增率，從2021年的16億美元增至2022年的17億美元，預計到2023年將達到18億美元。這一上升趨勢表明，寵物主人和獸醫越來越意識到管理動物疼痛對於提高其生活品質的重要性。此外，包括緩釋和調味口服藥物在內的先進藥物劑型的推出，使寵物主人和獸醫專業人員能夠更輕鬆地進行疼痛緩解，從而進一步提高了採用率。透皮貼片等創新給藥系統的發展也在簡化治療方案和改善患者預後方面發揮了關鍵作用。

按動物類型分類，2024年，狗佔據市場主導地位，創造了11億美元的收入，預計到2034年將成長至19億美元，複合年成長率為6.1%。這主要是由於狗的數量眾多，且該群體中骨科疾病和慢性疾病的患病率較高，這極大地刺激了對疼痛緩解療法的需求。

就產品類型而言，市場細分為藥品和器械。藥品領域在2024年引領全球市場，佔據總市場佔有率的81.7%，預計在預測期內將以6%的複合年成長率成長。藥物因其起效迅速且能有效治療多種疼痛疾病，仍是獸醫的第一線治療手段。該領域包括非類固醇抗發炎藥、鴉片類藥物、麻醉藥和其他藥物類別。長效製劑和更易給藥的藥物等藥物創新的不斷進步，推動了獸醫護理中對藥物治療的日益青睞。

根據應用，市場分為骨關節炎和關節痛、癌症、術後疼痛和其他用途。骨關節炎和關節痛細分市場在2024年的估值為8.072億美元，預計在2025年至2034年期間的複合年成長率為6.4%。寵物（尤其是貓狗）中與年齡相關的關節疾病的增加是該細分市場擴張的關鍵因素。由於放射影像學、步態分析和活動追蹤工具等診斷技術的進步，獸醫專業人員現在能夠更早診斷關節問題，從而導致治療率激增，並推動了對疼痛管理解決方案的需求。

美國伴侶動物疼痛管理市場規模從2023年的7.542億美元成長至2024年的7.957億美元。預測期內，美國市場複合年成長率可望達到5.9%。這一成長背後有幾個因素，包括寵物肌肉骨骼疾病的高發性、寵物飼養率的上升以及先進獸醫護理基礎設施的普及。越來越多的寵物主人將寵物的健康放在首位，這體現在擴大採用現代疼痛緩解方法，包括再生醫學和替代療法。涵蓋各種疼痛治療的保險計劃的出現，進一步改善了人們獲得醫療服務的機會。

全球前五大公司佔據了約45%的市場。在競爭激烈的市場中，不乏一些知名企業，它們提供針對肌肉骨骼疼痛、髖關節發育不良和關節炎等疾病的先進止痛解決方案。這些公司憑藉著豐富的產品線、穩固的品牌影響力和廣泛的分銷管道，穩固了其市場地位。他們對研發的專注，以及日益成長的創新意識，正在持續塑造伴侶動物疼痛管理的未來。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 寵物擁有量的成長和寵物的人性化
    • 老年寵物患有關節炎和慢性疼痛的病例不斷增加
    • 疼痛管理藥物和設備的進步
    • 獸醫保健支出增加
  • 產業陷阱與挑戰
    • 獸醫疼痛管理治療費用高昂
    • 疼痛管理藥物的嚴格法規核准
• 成長潛力分析
• 管道分析
• 未來趨勢
• 監管格局
• 川普政府關稅
  • 對貿易的影響
    • 貿易量中斷
    • 報復措施
  • 對產業的影響
    • 供給側影響（原料）
      • 主要材料價格波動
      • 供應鏈重組
      • 生產成本影響
    • 需求面影響（售價）
      • 價格傳導至終端市場
      • 市佔率動態
      • 消費者反應模式
  • 受影響的主要公司
  • 策略產業反應
    • 供應鏈重組
    • 定價和產品策略
    • 政策參與
  • 展望與未來考慮
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按動物類型，2021 - 2034 年

• 主要趨勢
• 狗
• 貓
• 馬匹
• 其他動物類型

第6章：市場估計與預測：依產品類型，2021 - 2034 年

• 主要趨勢
• 藥物
  • 類型
    • 非類固醇抗發炎藥（NSAIDS）
    • 鴉片類藥物
    • 麻醉藥
    • 其他藥物類型
  • 給藥途徑
    • 口服
    • 腸外
    • 外用
  • 配銷通路
    • 獸醫院藥房
    • 零售藥局
    • 網路藥局
• 裝置
  • 雷射治療
  • 電磁療法

第7章：市場估計與預測：按應用，2021 - 2034 年

• 主要趨勢
• 骨關節炎和關節痛
• 癌症
• 術後疼痛
• 其他應用

第8章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Aurora Pharmaceutical
• Bimeda
• Boehringer Ingelheim
• Ceva Sante Animale
• Chanelle Pharma
• Companion Animal Health
• Dechra Pharmaceuticals
• Elanco
• INDIBA
• Merck
• Norbrook
• PainTrace
• Vetaquinol
• Vetnation Pharma
• Virbac
• Zoetis

The global companion animal pain management market was valued at USD 1.9 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 3.4 billion by 2034. This steady growth is fueled by the increasing incidence of chronic conditions in pets, which has led to a greater demand for effective pain relief solutions. Alongside this, technological progress in veterinary therapeutics and the rising number of dedicated pain management facilities are contributing significantly to market expansion. As companion animals live longer due to improved veterinary care, conditions such as osteoarthritis, post-surgical discomfort, and cancer-related pain are becoming more prevalent, creating a higher need for accessible and efficient pain management tools. The industry encompasses a wide range of pharmaceutical products such as NSAIDs, opioids, and anesthetics, as well as medical devices aimed at alleviating both acute and chronic pain in animals like dogs, cats, horses, and others.

Between 2021 and 2023, the market displayed consistent year-over-year growth, increasing from USD 1.6 billion in 2021 to USD 1.7 billion in 2022 and reaching USD 1.8 billion by 2023. This upward trend indicates an increasing awareness among pet owners and veterinarians about the importance of managing pain in animals to enhance their quality of life. Furthermore, the introduction of advanced drug formulations, including extended-release and flavored oral medications, has made it easier for both pet owners and veterinary professionals to administer pain relief, further boosting adoption rates. The development of innovative drug delivery systems, such as transdermal patches, has also played a critical role in simplifying treatment protocols and improving patient outcomes.

By animal type, dogs held the dominant market position in 2024, generating USD 1.1 billion in revenue and expected to grow to USD 1.9 billion by 2034 at a CAGR of 6.1%. This is largely due to the high dog population and the greater prevalence of orthopedic and chronic conditions in this group, which significantly contribute to the demand for pain relief therapies.

In terms of product type, the market is segmented into drugs and devices. The drugs segment led the global market in 2024, capturing 81.7% of the total share, and is anticipated to grow at a CAGR of 6% over the forecast period. Drugs remain the first-line treatment for veterinarians due to their rapid onset and effectiveness in managing a wide range of pain conditions. This segment includes NSAIDs, opioids, anesthetics, and other drug classes. The continuous enhancement in pharmaceutical innovation, such as long-acting formulations and easier-to-administer medications, supports the growing preference for drug-based treatments in veterinary care.

Based on application, the market is divided into osteoarthritis and joint pain, cancer, postoperative pain, and other uses. The osteoarthritis and joint pain segment garnered a valuation of USD 807.2 million in 2024 and is forecasted to grow at a CAGR of 6.4% between 2025 and 2034. The rise in age-related joint disorders among pets, particularly dogs and cats, is a key factor in this segment's expansion. Veterinary professionals are now able to diagnose joint problems earlier, thanks to advancements in diagnostic technologies such as radiography, gait analysis, and mobility tracking tools, leading to a surge in treatment rates and driving the demand for pain management solutions.

The companion animal pain management market in the United States was valued at USD 795.7 million in 2024, growing from USD 754.2 million in 2023. The country is poised to expand at a CAGR of 5.9% during the forecast period. Several factors underpin this growth, including the high occurrence of musculoskeletal issues in pets, the increasing rate of pet ownership, and access to advanced veterinary care infrastructure. More pet owners are prioritizing the well-being of their animals, which is reflected in the greater adoption of modern pain relief options, including regenerative medicine and alternative therapies. The availability of insurance plans that cover various pain treatments has further improved access to care.

Around 45% of the global market share is held by the top five companies. This competitive landscape includes several prominent players offering advanced pain relief solutions tailored for conditions like musculoskeletal pain, hip dysplasia, and arthritis. These companies maintain their market positions through extensive product offerings, well-established brand presence, and wide-reaching distribution channels. Their focus on research and development, coupled with a growing emphasis on innovation, continues to shape the future of pain management for companion animals.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing pet ownership and humanization of pets
    • 3.2.1.2 Rising cases of arthritis and chronic pain in aging pets
    • 3.2.1.3 Advances in pain management drugs and devices
    • 3.2.1.4 Increasing expenditure on veterinary healthcare
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of veterinary pain management treatments
    • 3.2.2.2 Strict regulatory approvals for pain management drugs
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Future trends
• 3.6 Regulatory landscape
• 3.7 Trump administration tariffs
  • 3.7.1 Impact on trade
    • 3.7.1.1 Trade volume disruptions
    • 3.7.1.2 Retaliatory measures
  • 3.7.2 Impact on the Industry
    • 3.7.2.1 Supply-side impact (raw materials)
      • 3.7.2.1.1 Price volatility in key materials
      • 3.7.2.1.2 Supply chain restructuring
      • 3.7.2.1.3 Production cost implications
    • 3.7.2.2 Demand-side impact (selling price)
      • 3.7.2.2.1 Price transmission to end markets
      • 3.7.2.2.2 Market share dynamics
      • 3.7.2.2.3 Consumer response patterns
  • 3.7.3 Key companies impacted
  • 3.7.4 Strategic industry responses
    • 3.7.4.1 Supply chain reconfiguration
    • 3.7.4.2 Pricing and product strategies
    • 3.7.4.3 Policy engagement
  • 3.7.5 Outlook and future considerations
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dogs
• 5.3 Cats
• 5.4 Horses
• 5.5 Other animal types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drugs
  • 6.2.1 Type
    • 6.2.1.1 Non-steroidal anti-inflammatory drugs (NSAIDS)
    • 6.2.1.2 Opioids
    • 6.2.1.3 Anesthetics
    • 6.2.1.4 Other drug types
  • 6.2.2 Route of administration
    • 6.2.2.1 Oral
    • 6.2.2.2 Parenteral
    • 6.2.2.3 Topical
  • 6.2.3 Distribution channel
    • 6.2.3.1 Veterinary hospitals pharmacies
    • 6.2.3.2 Retail pharmacies
    • 6.2.3.3 Online pharmacies
• 6.3 Devices
  • 6.3.1 Laser therapy
  • 6.3.2 Electromagnetic therapy

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Osteoarthritis & joint pain
• 7.3 Cancer
• 7.4 Postoperative pain
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Aurora Pharmaceutical
• 9.2 Bimeda
• 9.3 Boehringer Ingelheim
• 9.4 Ceva Sante Animale
• 9.5 Chanelle Pharma
• 9.6 Companion Animal Health
• 9.7 Dechra Pharmaceuticals
• 9.8 Elanco
• 9.9 INDIBA
• 9.10 Merck
• 9.11 Norbrook
• 9.12 PainTrace
• 9.13 Vetaquinol
• 9.14 Vetnation Pharma
• 9.15 Virbac
• 9.16 Zoetis